Literature DB >> 24648416

YB-1 transforms human mammary epithelial cells through chromatin remodeling leading to the development of basal-like breast cancer.

Alastair H Davies1, Kristen M Reipas, Mary Rose Pambid, Rachel Berns, Anna L Stratford, Abbas Fotovati, Natalie Firmino, Arezoo Astanehe, Kaiji Hu, Christopher Maxwell, Gordon B Mills, Sandra E Dunn.   

Abstract

There is growing evidence that cancer-initiation could result from epigenetic changes. Y-box binding protein-1 (YB-1) is a transcription/translation factor that promotes the formation of tumors in transgenic mice; however, the underlying molecular events are not understood. To explore this in a human model system, YB-1 was expressed in mammary epithelial cells under the control of a tetracycline-inducible promoter. The induction of YB-1 promoted phenotypes associated with malignancy in three-dimensional breast acini cultures. This was attributed to YB-1 enhancing the expression and activity of the histone acetyltransferase p300 leading to chromatin remodeling. Specifically, this relaxation of chromatin allowed YB-1 to bind to the BMI1 promoter. The induction of BMI1 engaged the Polycomb complex resulting in histone H2A ubiquitylation and repression of the CDKN2A locus. These events manifested functionally as enhanced self-renewal capacity that occurred in a BMI1-dependent manner. Conversely, p300 inhibition with anacardic acid prevented YB-1 from binding to the BMI1 promoter and thereby subverted self-renewal. Despite these early changes, full malignant transformation was not achieved until RSK2 became overexpressed concomitant with elevated human telomerase reverse transcriptase (hTERT) activity. The YB-1/RSK2/hTERT expressing cells formed tumors in mice that were molecularly subtyped as basal-like breast cancer. We conclude that YB-1 cooperates with p300 to allow BMI1 to over-ride p16(INK4a) -mediated cell cycle arrest enabling self-renewal and the development of aggressive breast tumors.
© 2014 AlphaMed Press.

Entities:  

Keywords:  Breast cancer; Cancer stem cells; Epigenetics; Human mammary epithelial cells; Neoplastic cell transformation; Y-box binding protein-1

Mesh:

Substances:

Year:  2014        PMID: 24648416      PMCID: PMC4321723          DOI: 10.1002/stem.1707

Source DB:  PubMed          Journal:  Stem Cells        ISSN: 1066-5099            Impact factor:   6.277


  57 in total

1.  Highly multiplexed phenotypic imaging for cell proliferation studies.

Authors:  Paolo Cappella; Fabio Gasparri
Journal:  J Biomol Screen       Date:  2013-07-29

2.  Mutual regulation between Raf/MEK/ERK signaling and Y-box-binding protein-1 promotes prostate cancer progression.

Authors:  Kenjiro Imada; Masaki Shiota; Kenichi Kohashi; Kentaro Kuroiwa; YooHyun Song; Masaaki Sugimoto; Seiji Naito; Yoshinao Oda
Journal:  Clin Cancer Res       Date:  2013-07-09       Impact factor: 12.531

3.  Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells.

Authors:  Piyush B Gupta; Christine M Fillmore; Guozhi Jiang; Sagi D Shapira; Kai Tao; Charlotte Kuperwasser; Eric S Lander
Journal:  Cell       Date:  2011-08-19       Impact factor: 41.582

4.  Activation of MAPK pathways due to DUSP4 loss promotes cancer stem cell-like phenotypes in basal-like breast cancer.

Authors:  Justin M Balko; Luis J Schwarz; Neil E Bhola; Richard Kurupi; Phillip Owens; Todd W Miller; Henry Gómez; Rebecca S Cook; Carlos L Arteaga
Journal:  Cancer Res       Date:  2013-08-21       Impact factor: 12.701

5.  Met signaling regulates growth, repopulating potential and basal cell-fate commitment of mammary luminal progenitors: implications for basal-like breast cancer.

Authors:  S Gastaldi; F Sassi; P Accornero; D Torti; F Galimi; G Migliardi; G Molyneux; T Perera; P M Comoglio; C Boccaccio; M J Smalley; A Bertotti; L Trusolino
Journal:  Oncogene       Date:  2012-05-07       Impact factor: 9.867

6.  Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer.

Authors:  James S Duncan; Martin C Whittle; Kazuhiro Nakamura; Amy N Abell; Alicia A Midland; Jon S Zawistowski; Nancy L Johnson; Deborah A Granger; Nicole Vincent Jordan; David B Darr; Jerry Usary; Pei-Fen Kuan; David M Smalley; Ben Major; Xiaping He; Katherine A Hoadley; Bing Zhou; Norman E Sharpless; Charles M Perou; William Y Kim; Shawn M Gomez; Xin Chen; Jian Jin; Stephen V Frye; H Shelton Earp; Lee M Graves; Gary L Johnson
Journal:  Cell       Date:  2012-04-13       Impact factor: 41.582

7.  Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance.

Authors:  Justin M Balko; Rebecca S Cook; David B Vaught; María G Kuba; Todd W Miller; Neil E Bhola; Melinda E Sanders; Nara M Granja-Ingram; J Joshua Smith; Ingrid M Meszoely; Janine Salter; Mitch Dowsett; Katherine Stemke-Hale; Ana M González-Angulo; Gordon B Mills; Joseph A Pinto; Henry L Gómez; Carlos L Arteaga
Journal:  Nat Med       Date:  2012-07       Impact factor: 53.440

8.  Targeting p90 ribosomal S6 kinase eliminates tumor-initiating cells by inactivating Y-box binding protein-1 in triple-negative breast cancers.

Authors:  Anna L Stratford; Kristen Reipas; Kaiji Hu; Abbas Fotovati; Rachel Brough; Jessica Frankum; Mandeep Takhar; Peter Watson; Alan Ashworth; Christopher J Lord; Annette Lasham; Cristin G Print; Sandra E Dunn
Journal:  Stem Cells       Date:  2012-07       Impact factor: 6.277

9.  Functional viability profiles of breast cancer.

Authors:  Rachel Brough; Jessica R Frankum; David Sims; Alan Mackay; Ana M Mendes-Pereira; Ilirjana Bajrami; Sara Costa-Cabral; Rumana Rafiq; Amar S Ahmad; Maria Antonietta Cerone; Rachael Natrajan; Rachel Sharpe; Kai-Keen Shiu; Daniel Wetterskog; Konstantine J Dedes; Maryou B Lambros; Teeara Rawjee; Spiros Linardopoulos; Jorge S Reis-Filho; Nicholas C Turner; Christopher J Lord; Alan Ashworth
Journal:  Cancer Discov       Date:  2011-08-02       Impact factor: 39.397

10.  YB-1 evokes susceptibility to cancer through cytokinesis failure, mitotic dysfunction and HER2 amplification.

Authors:  A H Davies; I Barrett; M R Pambid; K Hu; A L Stratford; S Freeman; I M Berquin; S Pelech; P Hieter; C Maxwell; S E Dunn
Journal:  Oncogene       Date:  2011-03-21       Impact factor: 9.867

View more
  16 in total

1.  ERα Binding by Transcription Factors NFIB and YBX1 Enables FGFR2 Signaling to Modulate Estrogen Responsiveness in Breast Cancer.

Authors:  Thomas M Campbell; Mauro A A Castro; Kelin Gonçalves de Oliveira; Bruce A J Ponder; Kerstin B Meyer
Journal:  Cancer Res       Date:  2017-11-27       Impact factor: 12.701

Review 2.  A Tox21 Approach to Altered Epigenetic Landscapes: Assessing Epigenetic Toxicity Pathways Leading to Altered Gene Expression and Oncogenic Transformation In Vitro.

Authors:  Craig L Parfett; Daniel Desaulniers
Journal:  Int J Mol Sci       Date:  2017-06-01       Impact factor: 5.923

Review 3.  Centrosome amplification: a suspect in breast cancer and racial disparities.

Authors:  Angela Ogden; Padmashree C G Rida; Ritu Aneja
Journal:  Endocr Relat Cancer       Date:  2017-05-17       Impact factor: 5.678

4.  TMREC: A Database of Transcription Factor and MiRNA Regulatory Cascades in Human Diseases.

Authors:  Shuyuan Wang; Wei Li; Baofeng Lian; Xinyi Liu; Yan Zhang; Enyu Dai; Xuexin Yu; Fanlin Meng; Wei Jiang; Xia Li
Journal:  PLoS One       Date:  2015-05-01       Impact factor: 3.240

5.  Interplay between YB-1 and IL-6 promotes the metastatic phenotype in breast cancer cells.

Authors:  Bàrbara Castellana; Trond Aasen; Gema Moreno-Bueno; Sandra E Dunn; Santiago Ramón y Cajal
Journal:  Oncotarget       Date:  2015-11-10

6.  Inhibition of RSK with the novel small-molecule inhibitor LJI308 overcomes chemoresistance by eliminating cancer stem cells.

Authors:  Alastair H Davies; Kristen Reipas; Kaiji Hu; Rachel Berns; Natalie Firmino; Anna L Stratford; Sandra E Dunn
Journal:  Oncotarget       Date:  2015-08-21

7.  Etoposide enhances antitumor efficacy of MDR1-driven oncolytic adenovirus through autoupregulation of the MDR1 promoter activity.

Authors:  Bing-Hua Su; Gia-Shing Shieh; Yau-Lin Tseng; Ai-Li Shiau; Chao-Liang Wu
Journal:  Oncotarget       Date:  2015-11-10

8.  High expression of Y-box-binding protein 1 correlates with poor prognosis and early recurrence in patients with small invasive lung adenocarcinoma.

Authors:  Shilei Zhao; Wei Guo; Jinxiu Li; Wendan Yu; Tao Guo; Wuguo Deng; Chundong Gu
Journal:  Onco Targets Ther       Date:  2016-05-05       Impact factor: 4.147

9.  The 5'-untranslated region of p16INK4a melanoma tumor suppressor acts as a cellular IRES, controlling mRNA translation under hypoxia through YBX1 binding.

Authors:  Alessandra Bisio; Elisa Latorre; Virginia Andreotti; Brigitte Bressac-de Paillerets; Mark Harland; Giovanna Bianchi Scarra; Paola Ghiorzo; Robert C Spitale; Alessandro Provenzani; Alberto Inga
Journal:  Oncotarget       Date:  2015-11-24

10.  Regulators of genetic risk of breast cancer identified by integrative network analysis.

Authors:  Mauro A A Castro; Ines de Santiago; Thomas M Campbell; Courtney Vaughn; Theresa E Hickey; Edith Ross; Wayne D Tilley; Florian Markowetz; Bruce A J Ponder; Kerstin B Meyer
Journal:  Nat Genet       Date:  2015-11-30       Impact factor: 38.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.